A plain-English look at Eli Lilly's revenue, profit, and market value, and what those figures actually mean for a 150-year-old Indianapolis drugmaker.
Walk through Indianapolis and you're standing in the hometown of one of the most valuable drug companies on Earth. Eli Lilly & Co has been making medicine since 1875, but its financial profile today looks nothing like a typical century-old industrial company. It looks like a growth story that happens to also be enormous.
A Century-Old Company, A Modern Growth Curve
Lilly went public in July 1970, decades after it was founded, and has spent the years since building a business now anchored in neuroscience, cardiometabolic disease, cancer, and immunology. Its portfolio includes names many readers will recognize from doctor's offices and pharmacy counters: Mounjaro, Zepbound, and Jardiance for cardiometabolic conditions; Verzenio and Jaypirca for cancer; and Taltz and Olumiant for immunology.
What the Company Actually Sells
These aren't niche treatments. They span some of the most common and consequential health conditions in the country, which helps explain why demand — and revenue — has moved so quickly.
Revenue Scale and Growth
In fiscal 2025, Lilly generated $65.2 billion in revenue. That figure alone places it among the largest pharmaceutical companies anywhere, but the more striking number is the trajectory: revenue grew 130% between fiscal 2021 and fiscal 2025. A company doubling and then some in four years, at this size, is unusual — most businesses this large grow in single digits, not triple digits.
Where That Growth Shows Up
Growth at this scale typically reflects strong uptake of newer products alongside the steady performance of established ones, spread across a workforce of roughly 50,000 employees supporting research, manufacturing, and commercial operations.
Profitability: What the Margins Mean
Lilly turned $20.6 billion of that $65.2 billion in revenue into net income — a net margin of 31.7%. In plain terms, for every dollar of sales, nearly 32 cents flowed through to the bottom line. That's a high margin for any industry, let alone one with the heavy research and manufacturing costs pharmaceuticals require.
Gross Margin Tells a Related Story
The company's gross margin sits at 83.0%, meaning the direct cost of producing its medicines is a relatively small slice of what it charges. The gap between that gross figure and the net margin reflects everything else a drugmaker has to fund: research, regulatory work, sales forces, and administration.
Balance Sheet and Market Value
Lilly holds $112.5 billion in total assets, the accumulated value of its manufacturing plants, cash, intellectual property, and other resources. Investors currently value the company at a market capitalization of $1.0 trillion, with shares recently trading at $1,188.58, about 4% below their 52-week high.
Reading the P/E Ratio
The stock trades at a price-to-earnings ratio of 51.8, meaning the market price reflects roughly 52 times the company's per-share earnings. A ratio that high generally signals that investors expect continued strong growth, not just current profits, though it's simply a snapshot of market sentiment rather than a prediction of future performance.
Dividend and What It Signals
Lilly pays a dividend yielding about 0.58% annually. That's a modest yield relative to many mature companies, which often points to a business reinvesting more heavily in growth than in shareholder payouts — consistent with the rapid revenue expansion seen over the past four years.
The Bottom Line
Taken together, the figures describe a large, profitable pharmaceutical company that has grown its revenue dramatically in a short span while maintaining unusually high margins. This article is factual reporting drawn from public filings and market data, and is not investment advice.
